Short answer
MBX Biosciences, Inc. (MBX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$37M
- −91.1% YoY · −57.7% QoQ
- EPS (diluted)
- −$0.79
- −33.9% YoY · −58.0% QoQ
Source: XBRL data from the MBX Biosciences, Inc. (MBX) Q2 2026 10-Q on SEC EDGAR. USD.
MBX Biosciences, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0 in both quarters; no product sales or approved products
- Net loss $37.1M vs $19.4M YoY; operating loss $40.9M vs $21.8M
- R&D expense $31.0M vs $17.7M; canvuparatide highest program spend at $13.9M
- Cash, equivalents and marketable securities $418.6M vs $373.7M; funding expected into 2029
- Phase 3 canvuparatide trial planned for Q3 2026; MBX 4291 cohort results expected Q4 2026
Risk Factors
- No material changes to risk factors disclosed in the 2025 Annual Report
- Clinical-stage biotechnology exposure to development and commercialization risks remains significant
- Regulatory approval uncertainty remains a core risk for MBX Biosciences’ drug candidates
- Limited operating history and ongoing losses remain relevant to near-term performance
- Common-stock investment risk includes potential trading-price declines and total investment loss
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MBX Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.